The Trump administration has reached a landmark agreement with Eli Lilly and Novo Nordisk to reduce prices for their popular weight-loss medications. In exchange, the pharmaceutical giants will receive tariff relief and expanded Medicare access. President Trump announced the deal from the Oval Office, highlighting his administration’s efforts to lower healthcare costs.
about Trump Cuts Drug Prices for Lilly, Novo in Tariff Deal
FinanceNews Article 
November 7, 2025 | 00:00
November 7, 2025 | 00:00
FinanceNews Article November 6, 2025 | 23:59
November 6, 2025 | 23:59
FinanceNews Article November 6, 2025 | 20:16
November 6, 2025 | 20:16
FinanceNews Article November 5, 2025 | 14:31
November 5, 2025 | 14:31
FinanceMarket Report November 4, 2025 | 21:15
November 4, 2025 | 21:15
Novo Nordisk
5 posts last week
Trump Cuts GLP-1 Drug Prices, Expands Medicare Coverage
The Trump administration has secured a groundbreaking agreement with pharmaceutical giants Eli Lilly and Novo Nordisk that will dramatically reduce prices for GLP-1 medications while expanding Medicare coverage for obesity treatment for the first time. The deal, announced Thursday, brings some monthly drug costs down to approximately $250 and establishes price caps for future medications, marking a significant shift in healthcare policy that could pressure insurers to revisit restrictive coverage rules that have limited patient access to these transformative treatments.
about Trump Cuts GLP-1 Drug Prices, Expands Medicare CoverageLilly, Novo Cut Drug Prices for Medicare in Trump Deal
In a landmark pharmaceutical pricing agreement, Eli Lilly & Co. and Novo Nordisk A/S have secured deals with the Trump administration to significantly reduce prices for their blockbuster weight-loss drugs. The arrangement, announced Thursday at a White House event with President Donald Trump, provides the pharmaceutical giants with tariff relief in exchange for making these highly sought-after medications available to certain Medicare patients, representing a major shift in drug pricing policy and access for older Americans.
about Lilly, Novo Cut Drug Prices for Medicare in Trump DealNYC Elects Socialist Mayor Amid Record US Shutdown
New York City has elected its first democratic socialist mayor in a landmark political shift for the financial capital, while the US government shutdown has become the longest in history, creating mounting economic pressure. Financial leaders from Barclays, Novo Nordisk, and Jefferies weigh in on the implications of these parallel developments that are reshaping the economic landscape.
about NYC Elects Socialist Mayor Amid Record US ShutdownWall Street CEOs Warn of 10% Stock Correction Ahead
Wall Street CEOs are sounding alarm bells, predicting a potential 10% market correction within the next 12-24 months. The warning comes as Palantir’s AI-driven earnings fail to meet expectations, adding to growing investor concerns. Meanwhile, major pharmaceutical companies intensify their bidding war for Metsera while New York voters head to the polls in an election that could reshape the capital of capitalism.
about Wall Street CEOs Warn of 10% Stock Correction AheadChipotle Slump, Meta Bond Sale, Novo-Pfizer Bidding War
Today’s market action reveals significant cross-sector movements as consumer caution, corporate financing strategies, and pharmaceutical consolidation take center stage. Chipotle’s warning about consumer pullback is sending shockwaves through fast-casual restaurant stocks, while Meta Platforms executes one of the largest corporate bond sales in recent memory, and Novo Nordisk engages Pfizer in a high-stakes bidding war for Metsera. These developments highlight the diverse forces currently shaping market dynamics across consumer discretionary, technology, and healthcare sectors.
about Chipotle Slump, Meta Bond Sale, Novo-Pfizer Bidding WarTrump’s Ozempic Price Comments Hit Novo Nordisk, Lilly Shares
Pharmaceutical giants Novo Nordisk and Eli Lilly faced immediate market pressure after former President Donald Trump declared that the price of diabetes drug Ozempic could plummet to just $150 monthly—a dramatic reduction from its current $1,000 list price. Trump’s Oval Office comments specifically targeted what he called ‘the fat loss drug’ and suggested similar pricing for Lilly’s competing treatments Mounjaro and Zepbound, threatening the dominant position of both companies in a market projected to exceed $95 billion by 2030.
about Trump's Ozempic Price Comments Hit Novo Nordisk, Lilly SharesMarket Jitters: Bank Stocks Fall, Credit Fears Deepen
US financial markets face renewed pressure as bank stocks tumble amid deepening credit concerns, with Zions Bancorp and Western Alliance leading a sector-wide selloff following fraud allegations. Simultaneously, pharmaceutical giants Novo Nordisk and Eli Lilly decline after former President Trump’s comments about potential Ozempic price reductions, while the auto industry anticipates tariff relief on imported parts. The market turbulence reflects broader anxieties as Treasuries extend their rally and the dollar heads for its largest weekly drop since July.
about Market Jitters: Bank Stocks Fall, Credit Fears DeepenCostco Stock Correction: Buying Opportunity or Overpriced?
Costco shares have entered correction territory, falling 14% from recent highs despite maintaining premium valuations. The retail giant’s expansion into weight-loss medications and resilient business model present both opportunities and valuation concerns for investors navigating current market conditions.
about Costco Stock Correction: Buying Opportunity or Overpriced?Lupin Shares Drop 2% After USFDA OAI Classification
Lupin Ltd shares dropped 2% on October 6th as investors reacted to the US Food and Drug Administration’s classification of its Pithampur Unit 2 inspection as ‘official action indicated’ (OAI), signaling significant regulatory compliance concerns. The pharmaceutical company faces this setback even as it launches Liraglutide injection in the lucrative US diabetes market, creating a complex narrative of regulatory challenges and growth opportunities.
about Lupin Shares Drop 2% After USFDA OAI Classification